METHODS FOR TREATMENT OF ALPORT SYNDROME

摘要

The present invention is a method of treatment of Alport's syndrome using a modified oligonucleotide targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves renal function and/or reduces fibrosis in a subject suffering from Alport's syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject suffering from Alport's syndrome. In certain embodiments, modified oligonucleotides targeted to miR-21 delay the need for dialysis or kidney transplantation in a subject suffering from Alport's syndrome.